Abstract
Propamidine, one of the diamidines used against infections with babesiae has inhibitory and enhancing effects on complement activation as assessed by immune haemolysis of sensitized sheep red cells. Utilization of C1 is powerfully, that of C3 weakly improved by propamidine while activation and/or fixation of C4, C5 and to a lesser degree of C8 and C9 are inhibited. At low concentrations of propamidine (less than 2 mM) the enhancing effects, at higher concentrations the inhibitory effects predominate. Inhibition is produced, in some cases certainly, in others likely, by interference of propamidine with binding properties of complement components. None of the complement enzymes, C1s, C42 or C3bBb was inhibited in its hydrolytic activity. The possible significance of propamidine actions is discussed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Asghar S. S., Cormane R. H. Interaction of the B-determinant of the third component of complement with amidino compounds. Immunochemistry. 1976 Dec;13(12):975–978. doi: 10.1016/0019-2791(76)90267-6. [DOI] [PubMed] [Google Scholar]
- Brade V., Lee G. D., Nicholson A., Shin H. S., Mayer M. M. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway. J Immunol. 1973 Nov;111(5):1389–1400. [PubMed] [Google Scholar]
- Dieminger L., Vogt W., Lynen R. Purification and some properties of factor D of the human properdin system. Z Immunitatsforsch Immunobiol. 1976 Nov;152(3):231–243. [PubMed] [Google Scholar]
- Gigli I., Porter R. R., Sim R. B. The unactivated form of the first component of human complement, C1. Biochem J. 1976 Sep 1;157(3):541–548. doi: 10.1042/bj1570541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gigli I., von Zabern I., Porter R. R. The isolation and structure of C4, the fourth component of human complement. Biochem J. 1977 Sep 1;165(3):439–446. doi: 10.1042/bj1650439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lynen R., Brade V., Wolf A., Vogt W. Purification and some properties of a heat labile serum factor (UP); identity with glycine-rich beta-glycoprotein and properdin factor B. Hoppe Seylers Z Physiol Chem. 1973 Jan;354(1):37–47. doi: 10.1515/bchm2.1973.354.1.37. [DOI] [PubMed] [Google Scholar]
- Molenaar J. L., Müller M. A., Engelfriet C. P., Pondman K. W. Changes in antigenic properties of human C3 upon activation and conversion by trypsin. J Immunol. 1974 Apr;112(4):1444–1451. [PubMed] [Google Scholar]
- Polley M. J., Müller-Eberhard H. J. Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med. 1967 Dec 1;126(6):1013–1025. doi: 10.1084/jem.126.6.1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vogt W., Schmidt G., Hinsch B. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation. Immunology. 1979 Jan;36(1):139–143. [PMC free article] [PubMed] [Google Scholar]